The new Centre was opened by Jo Johnson, Minister of State for Universities and Science and Steve Bagshaw, CEO of Fujifilm Diosynth Biotechnologies. The new Centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.
Biopharmaceuticals are medicines produced through biotechnology which represent the cutting-edge of biomedical research. They are delivering significant advances in healthcare with completely new medicines being developed for serious illnesses, including cancer, blood conditions, auto-immune disorders such as rheumatoid arthritis, and neurological disorders like multiple sclerosis. The use of biotechnology can also facilitate the development of the next generation of personalised medicines for specific diseases and patient groups.
The National Biologics Manufacturing Centre was announced in 2012 as part of the UK strategy for Life science. The Strategy outlined a vision for the UK to be a global leader in the life science sector. The £38m investment was made by the Department for Business Innovation and Skills through InnovateUK.
CPI is the process industry element of the UK government’s High Value Manufacturing Catapult – the network of technology and innovation centres tasked with stimulating growth within key manufacturing sectors throughout the UK. CPI works with industry, academia and the public sector to develop, prove, prototype and scale up the next generation of products and processes.
Let’s innovate together
To find out more about how we can work together, please enter your details below. More contact options